Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.63 |
| ▸ | THRA | P10827 | 14/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515707 | 0.93 | THRB (0.60) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL7086230 | 0.86 | THRA (0.60) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6512292 | 0.86 | THRA (0.59) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6524751 | 0.84 | THRB (0.62) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6511447 | 0.84 | THRB (0.62) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6514228 | 0.84 | THRB (0.60) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6515758 | 0.82 | THRA (0.60) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL7082352 | 0.81 | THRA (0.69) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL7091262 | 0.81 | THRA (0.61) | THRBTHRAHTR2AHTR2CHTR2B | |
| SCHEMBL6521769 | 0.81 | THRB (0.57) | THRBTHRAHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227549-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1347959-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
| WO-2002051805-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | THRB 1772/4885THRA 2460/4885HTR2A 11/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | THRB 1835/4885THRA 1917/4885HTR2A 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.